Posted by AGORACOM-JC
at 6:53 PM on Thursday, January 21st, 2021
Today’s press release from HPQ might have been a little technical for newcomers but the words from CEO Bernard Tourillon explain exactly how important it was:
“With the Gen1 PUREVAP TM NSiR operational and exceeding expectations from the start, HPQ NANO is uniquely positioned to be at the forefront of low-cost manufacturing of Nano Silicon for batteries and other applications ….. We are very confident that the Silicon materials we are producing, with our expected low-cost scalable processes, will be in high demand by batteries, EV manufacturers and other participants in the ongoing renewable energy revolution.”
Moreover, Tourillon couldn’t help but display his feelings and proclaimed this was going to be a fun year for HPQ.
Posted by AGORACOM-JC
at 6:55 PM on Wednesday, January 20th, 2021
Let us start off by saying this interview may be the best one we’ve done in the last 10 years. Here is why.
When Mountain Valley MD issued this press release today, you wouldn’t be alone if you declared “I really don’t know what that means”. The fact of the matter is that MVMD is a double-edged sword that puts it in a position to quite potentially change the way the world delivers drugs and vaccines via physical transport and into the body of patients who need them most. The flip-side of creating something so cutting edge is that it makes it very difficult to understand for anybody without a Life Sciences PhD.
Fortunately, this is where AGORACOM comes in to bridge the worlds between MVMD and the investment community. To do that, the first thing you have to understand is the following:
MVMD Takes Existing Vaccines and Drugs – And Delivers Them Better. Both Into The Body and By Transportation To The World. Way Better.
For the purposes of introducing you to MVMD, we’ll use vaccines as an example given the state of the world since COVID-19 arrived. Specifically, we’ve all heard more about vaccines in 12 months than we have in the last 12 years. One thing we all know about vaccines is that vaccination is the safest way to protect people against infectious diseases.
BUT
One thing we don’t know or understand about vaccinations is that they are only as good as:
1. The global physical delivery system that actually gets them from the manufacturer to the hands of nurse who injects the vaccine;
2. The delivery system into your body (i.e. injection)
If either parts of these delivery systems are weak, or even fail, a vaccine loses some or even all of its potency – and that’s not good.
This is where MVMD comes in. They don’t make vaccines, drugs or pharmaceuticals.
What they do is make their delivery better. Their physical delivery until their ultimate delivery into your body – and that is very good.
By doing so, they help save lives and they help manufacturers be more profitable – and that is very good for humanity and shareholders.
CAN MVMD CREATE A WORLD WITHOUT POLIO … AND THEN OTHER VIRUSES? THEY JUST MIGHT
With the information above in mind, you can now start to get a sense of the power of this quote from MVMD CEO, Dennis Hancock:
“Using a fraction of the Inactivated Polio Vaccine, applying advanced Quicksome™ thin film inside a vial that can be distributed completely outside of the cold chain, and administering through needleless applications is the formula to help us achieve our vision of a world without Polio“.
If you want to find out what is possible, watch this powerful, eye-opening and sometimes emotional interview with CEO Dennis Hancock and Director of Life Sciences Mike Farber.
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
When we look back at 2020 this time next year … what we’ve done is very little in my opinion to date.”
Wait … What?
“This year (2021) will see major growth and expansion …. We’re about to reap the rewards from all the groundwork and that is exciting to me … This will be our biggest year by a country mile”
Given the fact we had to do this interview on a Sunday due to Anson “putting in 100 work weeks” and “18-20 Zoom presentations per day”, as well as, 4 pretty significant press releases in the first 2 weeks of 2021, Anson is living up to his word.
Moreover, in this interview, he shows no hesitation when asked if he still feels the same way about 2021.
Watch this great Sunday morning interview with Loop Insights Founder and CEO, Rob Anson.
Posted by AGORACOM-JC
at 7:00 AM on Monday, January 18th, 2021
FansUnite Entertainment $FANS $FUNFF continues to live up to its name as the “Small Cap iGaming Super Company” by yet again announcing major news.
Specifically, their originally announced $5M financing was upsized to $11,000,000 …. and then upsized AGAIN to $13,400,000. And according to CEO Scott Burton, the demand was much higher but they had to make a decision to cut it off at some point.
This should tell you all you need to know about how much demand there is for this small cap online gambling company, who recently made history by becoming the first EVER dedicated esports sportsbook in the United States, along with partner GameCo.
What we love about the Company is having both B2C (direct gambling customers) and B2B (providing the world’s online casinos with new games and technology).
Moreover, they were granted their all important Malta license recently, are now pursuing the invaluable UK license and finally, appear to be in pole position for anticipated changes to online gambling laws in Canada later in 2021.
Watch this amazing interview with $FANS CEO, Scott Burton
Posted by AGORACOM-JC
at 8:34 PM on Thursday, January 14th, 2021
Datamerex (DM:TSXV) has the rare benefit that most small cap companies would only dream of …. 2 successful independent divisions that are each capable of being a company maker.
The first division is their Artificial Intelligence driven social media monitoring and discovery product … and this isn’t some basic social media monitoring tool for keywords. Clients include Canadian Federal Government, DRDC, Health Canada, United States Air Force and LOTTE (a $2.6B South Korean multinational conglomerate.
As a result of the highest level security clearances required to do this level of work, Datametrex was well positioned with deep roots in South Korea to add their second, though unintended division of COVID-19 test kit distribution. Again, this isn’t some small cap stretch trying to capitalize on a trend for the sake of stock promotion. Rather, when the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar COVID-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.
As a result, Datametrex has had its’ best year ever in the first 3 quarters of 2020 as follows:
Record revenue of $7.6 million for the nine-month 2020 period compared to $2.6 in 2019
Record revenue of $4.9 million was generated in Q3
First ever positive EBIDTA quarter
If that wasn’t enough, they started off 2021 by announcing the following:
Sold over 23,000 onsite tests for the film industry at locations in Montreal, Toronto and Vancouver for the months of October through December 2020. This represents approximately $4,000,000 CAD in top-line revenue for Q4
Datametrex Providing COVID-19 Testing for Air Canada Front-Line and Inflight Employees
Binding LOI to acquire 100% of Concierge Medical Consultant Inc. a private telehealth and medical concierge services company currently generating revenue through a direct-to-consumer subscription model
Watch this powerful interview with CEO Marshall Gunter to discuss the year that was … and why he’s so optimistic about 2021.
Posted by AGORACOM-JC
at 8:04 AM on Thursday, January 14th, 2021
Most of us know drones as cool toys flying around the neighbourhood, or perhaps even as simple commercial applications for things like real estate videos.
But the fact of the matter is that drone usage is about to go parabolic with huge corporations now testing ways to:
Use drones to provide Internet connections in remote locations.
Use drones to collect crowd data.
….. And there’s even a start-up that’s using drones to deliver tacos to your door.
In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones (hardware) to data … and one company is already ahead of the shift … DraganFly (DFLY: CSE) (DFLYF:OTCQB) (3U8:FSE)
DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:
Established in 1998 DFLY is considered the oldest commercial drone company in the world
Built the first drone that saved a life
Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
Detect infectious conditions in a person from a distance of 190 feet
Conduct phenotyping, data collection and analysis by the USDA
With all of this under the Company’s belt, it’s easy to see why CEO Chell believes DFLY will become one of the top 3 drone companies in the world and why they have now begun the process of listing on NASDAQ.
If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or are just learning, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.
Posted by AGORACOM-JC
at 6:03 PM on Wednesday, January 13th, 2021
The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.
If you believe in the massive paradigm shift towards plant based foods and more, be sure to watch and share this great interview with PlantX Life Founder, Sean Dollinger.
You won’t just learn about a great small cap company, you’ll also learn how to live a healthier, tastier life.
Posted by AGORACOM-JC
at 6:29 PM on Tuesday, January 12th, 2021
2020 was a disappointing one for the once euphoric cannabis industry thanks to the fallout of over-hyped and over-financed companies that failed to deliver on a fraction of their promises.
The year 2000 saw the exact same thing happen to “dot-com” companies that failed in even more spectacular fashion. Many investors swore off internet stocks forever. The smart ones waited to see which companies were real … and the rest was history as we saw the birth and growth of internet companies that delivered real value, products and customers.
The same is about to happen in the Cannabis space in 2021. With the market estimated to hit $70 Billion over the next few years, there is very little doubt that winners will be created out of companies delivering real businesses
With Distribution and Manufacturing Agreements already in place for Both Europe and USA, $INNO is now on the verge of Commercializing It’s Clinically Proven CBD Products around the world in 2021.
As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.
If you believe in the future of the cannabis industry and companies delivering real, value-add CBD products, then watch this interview with Innocan CEO, Iris Bincovich.
